March 29, 2021 09:52 AM EDTUpdated March 30, 05:45 AM
R&D
Coronavirus

Eli Lil­ly, Glax­o­SmithK­line-Vir re­lease pos­i­tive but dif­fi­cult-to-in­ter­pret com­bo an­ti­body da­ta

Jason Mast

Editor

As vari­ants threat­ened Eli Lil­ly’s so­lo Covid-19 an­ti­body bam­lanivimab, the com­pa­ny teamed with ri­vals on a po­ten­tial com­bo ap­proach. Now they’ve de­clared in­ter­im suc­cess, though …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pfiz­er look­ing to sell hos­pi­tal drugs unit — re­ports

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

As­traZeneca CEO reaf­firms com­mit­ment to Chi­na fol­low­ing ex­ec­u­tive's de­ten­tion

Mer­ck, As­traZeneca tout Phase 3 win for can­cer-turned-rare dis­ease drug

Sanofi, Ope­nAI, For­ma­tion Bio de­but pa­tient re­cruit­ing tool, will use in Phase 3 mul­ti­ple scle­ro­sis stud­ies

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times